SAG
SRPT icon

SageView Advisory Group’s Sarepta Therapeutics SRPT Stock Holding History

SageView Advisory Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,173
Closed -$68.3K – 2187
2025
Q4 		$68.3K Buy
+3,173
New +$66.9K ﹤0.01% 955

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SageView Advisory Group's SRPT Position: Q1 2026 in Review

SageView Advisory Group sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 3,173 shares — an estimated $68.3K sold.

SageView Advisory Group first reported a position in SRPT in Q4 2025 and held it in 1 quarter. The position peaked at $68.3K in Q4 2025. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • SageView Advisory Group reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 3,173 Sarepta Therapeutics shares in Q1 2026, an estimated $68.3K.
  • SageView Advisory Group first reported a position in Sarepta Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Sarepta Therapeutics position peaked at $68.3K in Q4 2025.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.